vertex pharmaceuticals vrtx

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

Business Insider · 2d

Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare

AOL · 3d

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,

MarketWatch · 5d

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

Yahoo · 2d

FDA Approves the First Non-Opioid Pain Medicine in 20 Years

On Jan. 30, the U.S. Food and Drug Administration (FDA) approved a new drug called suzetrigine to treat moderate-to-severe pain. The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals,

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Zacks.com on MSN14h

Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Nasdaq3d

Should You Pick VRTX Stock At $450?

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Vertex Pharmaceuticals Unusual Options Activity

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

Zacks.com on MSN2d

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...

The Armenian Reporter14h

Optas LLC Buys 64 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Optas LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 7.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned ...

HC Wainwright Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price lifted by HC Wainwright from $535.00 to $550.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright ...

15h

An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses.

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results